Thailand Women’s Health Market Size & Outlook, 2023-2030
Thailand women’s health market, 2018-2030 (US$M)
Related Markets
Thailand women’s health market highlights
- The Thailand women’s health market generated a revenue of USD 105.2 million in 2023 and is expected to reach USD 181.3 million by 2030.
- The Thailand market is expected to grow at a CAGR of 8.1% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 105.2 million |
| Market revenue in 2030 | USD 181.3 million |
| Growth rate | 8.1% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Thailand accounted for 0.2% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan women’s health market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 3,966.1 million by 2030.
Contraceptives was the largest segment with a revenue share of 35.55% in 2023. Horizon Databook has segmented the Thailand women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
The osteoporosis prevalence among the country’s women aged less than 50 was less than 5%. The prevalence of this disease increased after the age of 50. The following table shows the age-specific prevalence of osteopenia and osteoporosis.
The rising disposable income, increasing awareness about health & wellness, and increasing awareness are among the major factors contributing to the women’s health market growth in the country.
For instance, in April 2023, Fuji Pharma launched Nextstellis (FSN-013) used for the prevention of pregnancy in Thailand. It is introduced to reduce the adverse effects of a combination of drugs containing estrogen.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Thailand women’s health market size, by application, 2018-2030 (US$M)
Thailand Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
